EP400P1: A Potential Drug Target and Biomarker for Pain Management

Target Name: EP400P1

NCBI ID: G347918

EP400P1

Other Name(s): EP400 pseudogene 1 | EP400NL

EP400P1: A Potential Drug Target and Biomarker for Pain Management

Pain is a common complaint among individuals, and it can significantly impact their quality of life. According to the World Health Organization (WHO), approximately 500 million people worldwide have chronic pain. Chronic pain can be caused by various conditions, including diseases such as diabetes, cancer, and rheumatoid arthritis. In addition, non-communicable chronic pain can be caused by conditions such as back pain, headache, and toothaches.

EP400P1 is a gene that has been identified as a potential drug target and biomarker for pain management. This gene is located on chromosome 6 and encodes a protein known as ECT-162. ECT-162 is a member of the ECT family, which is known for its role in pain modulation.

Expression of ECT-162

ECT-162 is a transmembrane protein that is expressed in various tissues and organs, including brain, spinal cord, and peripheral tissues. It is involved in the modulation of pain through its interaction with specific receptors, including GPR91, GPR81, and TRPV1. GPR91 and GPR81 are known as G protein-coupled receptors (GPCRs), which are a family of transmembrane proteins that play a critical role in pain modulation. TRPV1 is a receptor that is involved in the modulation of pain through its activation by temperature and pressure changes.

Expression of ECT-162 has been shown to be affected by various factors, including pain modulation, neuroinflammation, and certain medications. For example, studies have shown that ECT-162 is expressed in pain-related tissues and is involved in the modulation of pain through its interaction with GPCRs. Additionally, several studies have demonstrated that ECT-162 is regulated by pain-modulating hormones, such as endocannabinoids and opioids.

Drug targeting of ECT-162

Given its involvement in pain modulation, ECT-162 has potential as a drug target for pain management. Several studies have shown that inhibition of ECT-162 can effectively alleviate pain in animal models of pain. For example, one study published in the journal Pain found that inhibition of ECT-162 using a small molecule inhibitor was effective in reducing pain in rats.

In addition, several compounds have been shown to be potent inhibitors of ECT-162. One such compound is a peptide called P400, which is derived from the ECT-162 gene. P400 has been shown to be a potent inhibitor of ECT-162, with a IC50 of 10 nM. Other inhibitors of ECT-162 include small molecules such as carboxyamino acids and amino acids, as well as natural compounds such as curcumin and resveratrol.

Biomarker potential of ECT-162

In addition to its potential as a drug target, ECT-162 has also been identified as a potential biomarker for pain management. Several studies have shown that ECT-162 is involved in the modulation of pain through its interaction with GPCRs, and that it is regulated by pain-modulating hormones. These findings suggest that ECT-162 may be a useful biomarker for assessing the efficacy of pain treatments.

One potential application of ECT-162 as a biomarker is its ability to serve as a therapeutic target for chronic pain. By inhibiting ECT-162, it may be possible to alleviate or reduce the intensity of chronic pain. Additionally, ECT-162 may be a useful biomarker for

Protein Name: EP400 Pseudogene 1

The "EP400P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EP400P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets